Table 2.
Comparison between rechallenge and nonrechallenge cases after an irAE with at least 1 immune checkpoint inhibitor (n = 24 079)
| Initial irAE | No. (%), Rechallenge after irAE (n = 6123) | No rechallenge after irAE (n = 17 956) |
|---|---|---|
| ICI | ||
| Anti-PD-1 or anti-PD-L1 alone | 4360 (71.2) | 12 321 (68.6) |
| Anti-CTLA-4 alone | 791 (12.9) | 3290 (18.3) |
| Combination therapy | 972 (15.9) | 2345 (13.1) |
| Type of initial irAE (only five diseases with the highest rechallenge rate were selected) | ||
| Colitis | 1745 (28.5) | 5353 (29.8) |
| Pneumonitis | 1288 (21.0) | 4001 (22.3) |
| Thyroiditis | 779 (12.7) | 1977 (11.0) |
| Arthritis | 491 (8.0) | 1372 (7.6) |
| Hepatitis | 473 (7.7) | 1444 (8.0) |
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen-4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed cell death 1; PD-L1, programmed cell death 1 ligand 1.